

# Table of Contents

- 5 Foreword
- 6 R&D cuts by sponsors spur more collaboration, innovation
- 10 Operating environment spurs out-of-the-box ideas
- 15 Will end-to-end outsourcing take hold?
- 20 Medical device outsourcing poised to grow rapidly
- 24 Sponsors look to collaborate on comparator drugs
- 29 Early adopters implement risk-based monitoring pilot programs
- 33 Tracking major changes in the R&D pipeline
- 39 Strategic alliances hit bumps in the road
- 44 Global clinical trial laboratories decentralize
- 47 Lessons learned from medical device trials
- 50 Today's fastest, most efficient sponsors
- 56 Novo Nordisk, Takeda, Servier, Celgene among top sponsors
- 63 Job satisfaction mixed as workload increases
- 69 Pharma industry improves its tarnished reputation

# Table of Contents Continued

- 74 **TransCelerate Biopharma turns three**
- 78 **Global clinical trials: Calling the hype to task**
- 82 **New strategies needed for integrated alliances**
- 87 **Welcoming procurement onto the team**
- 90 **Payer influence makes inroads in clinical research**
- 95 **About CenterWatch**

# Foreword

I'm pleased to present the third report in the Compilation Report Series, the *Sponsor Compilation Report*, which covers the growth and collaboration between Sponsors and CROs, outsourcing models, new initiatives, innovation and ideas.

This report is a comprehensive compilation of archived CenterWatch stories based on in-depth interviews, investigative reporting and original research and analysis.

Topics include:

- ▶ R&D cuts by sponsors have spurred more collaboration and innovation within the industry. Alliances have been growing in scope and depth over the past few years as companies have recognized their challenges, institutions have sought industry funding and together have developed better mechanisms to deal with differences that arise.
- ▶ Medical device outsourcing has been growing rapidly as product development has become more complex, regulators require more rigorous data and sponsors seek to move into overseas markets.
- ▶ Major changes are being tracked in the R&D pipeline as recent growth in therapeutic areas has shifted. Sponsorship of the pipeline has changed significantly as small biopharmaceutical companies sponsor the majority of R&D activity.
- ▶ Integrated alliances are on the rise. Many companies have introduced new internal mechanisms to oversee strategic outsourcing partnerships. Lean outsourcing models, patient-centricity, adaptive design and the use of metrics will continue to strengthen strategic and integrated relationships.

For more than 20 years, CenterWatch has had the responsibility and privilege of dedicating its energies to objectively observing the clinical trials industry. CenterWatch has had a unique and unprecedented opportunity to serve as watch-dog, educator and curator.

We hope you enjoy reading this *Sponsor Compilation Report* and gaining more insight on the rapid growth and collaboration between sponsors and CROs as much as we have enjoyed the opportunity to report on it.

Joan A. Chambers  
Chief Operating Officer